Grown Rogue International (GRUSF) Cash from Investing Activities (2013 - 2026)
Grown Rogue International (GRUSF) posted quarterly Cash from Investing Activities of -$2.9 million for Q1 2026, down 761.12% year-over-year from $434808.6 in Q1 2025, and down 100.0% quarter-over-quarter from $1955.8 billion in Q4 2025.
Grown Rogue International (GRUSF) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Grown Rogue International's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$2.9 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 761.12% year-over-year to -$2.9 million; the TTM figure through Mar 2026 stood at $1955.8 billion (up 28569547.93% YoY), while the FY2025 annual figure was -$6.9 million, up 23.4% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$2.9 million, down from $1955.8 billion in the prior quarter.
- The five-year high for Cash from Investing Activities was $1955.8 billion in Q4 2025, with the low at -$2.9 million in Q1 2026.
- The 5-year median for Cash from Investing Activities is -$910381.0 (2023), against an average of $150.4 billion.
- The sharpest annual moves came in 2025 and 2026: Cash from Investing Activities surged 103863188.84% in 2025, then slumped 761.12% in 2026.
- Grown Rogue International's Cash from Investing Activities stood at -$455557.1 in 2022, then plunged by 361.53% to -$2.1 million in 2023, then climbed by 10.44% to -$1.9 million in 2024, then jumped by 103863188.84% to $1955.8 billion in 2025, then slumped by 100.0% to -$2.9 million in 2026.
- Business Quant data shows GRUSF's Cash from Investing Activities at -$2.9 million in Q1 2026, $1955.8 billion in Q4 2025, and -$394324.2 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Grown Rogue International | 109.32 Mn | 97.78 Mn | 5.37 Mn | -3.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.42 Mn |
| Jun 30, 2026 | -3.42 Mn |
| Mar 31, 2026 | -2.87 Mn |
| Mar 31, 2026 | -2.87 Mn |
| Dec 31, 2025 | 1,955.77 Bn |
| Dec 31, 2025 | 1,955.77 Bn |
| Jun 30, 2025 | -394,324.22 |
| Jun 30, 2025 | -394,324.22 |
| Mar 31, 2025 | -333,822.00 |
| Mar 31, 2025 | -333,822.00 |
| Dec 31, 2024 | -1.88 Mn |
| Dec 31, 2024 | -1.88 Mn |
| Sep 30, 2024 | -2.44 Mn |
| Sep 30, 2024 | -2.44 Mn |
| Jun 30, 2024 | -2.19 Mn |
| Jun 30, 2024 | -2.19 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Mar 31, 2024 | -2.41 Mn |
| Oct 31, 2023 | -2.10 Mn |
| Oct 31, 2023 | -2.10 Mn |